rachel baker, helen mason & neil mchugh glasgow caledonian university

13
Extending life for people with a terminal illness: a moral right or an expensive death? Empirical and methodological issues Rachel Baker, Helen Mason & Neil McHugh Glasgow Caledonian University Job van Exel Erasmus University Rotterdam

Upload: dean-contreras

Post on 01-Jan-2016

19 views

Category:

Documents


1 download

DESCRIPTION

Extending life for people with a terminal illness: a moral right or an expensive death? Empirical and methodological issues. Rachel Baker, Helen Mason & Neil McHugh Glasgow Caledonian University Job van Exel Erasmus University Rotterdam. Overview of the session. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

Extending life for people with a

terminal illness: a moral right or an

expensive death?

Empirical and methodological issuesRachel Baker, Helen Mason & Neil McHugh

Glasgow Caledonian University

Job van Exel Erasmus University Rotterdam

Page 2: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

Overview of the session

• Introduction to the project– Background– Research objectives– Methods

• Three presentations

• Discussion

Page 3: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

UK MRC Methodology Panel funding 2011-2014

“Is ‘end-of-life’ care more valuable? Measuring societal views on health care resource allocation using the new Q2S method.”

Rachel Baker, Neil McHugh, Helen Mason, Cam Donaldson, Laura Williamson, Jon Godwin,

(GCU)Marissa Collins, Rohan Deogaonkar

Job van Exel (Erasmus, Rotterdam)

Cathy Hutchinson (Beatson Cancer Centre, NHS Greater Glasgow &Clyde)

Page 4: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

Starting point of the study

• Scarcity and health care resource allocation in publicly funded health systems. → Under limited budgets, decisions must be made

about which treatments (not) to fund. • Considerations of fairness and relative value of

health gains benefiting different patient groups in different ways.→ Are equal sized health gains ‘worth’ the same

regardless of who benefits and in what ways?

Page 5: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University
Page 6: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

NICE End of life Supplementary guidance

• Specific criteria:– less than 2 years to live– treatments would result in a gain of at least 3 months

of increased life expectancy – drug is licensed for a relatively small patient group

“The Institute recognises that the public, generally, places special value on treatments that prolong life – even for a few months – at the end of life, as long as that extension of life is of reasonable quality (at least pain-free if not disability-free). NICE has therefore provided its advisory bodies with supplementary advice about the circumstances under which they should consider advising, as cost-effective, treatments costing >£30,000 per QALY.”Rawlins et al (2010) Brit j of Clinical Pharmacology, p 348

Page 7: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

Research Objectives

1. To identify and describe societal perspectives on the (relative) value of end of life technologies by eliciting the views of both members of the public and experts in relevant fields;

2. To develop methods to investigate the distribution of those views, including their association with other characteristics, in a nationally representative sample of the UK general public.

Q methodology

Survey methods

Methodological, quantitative

Empirical, qualitative

5,000 online questionnaire respondents

50 experts; 250 public; face to face Q sorts

Page 8: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

A little bit about Q methodology

• What is Q methodology? A set of connected techniques designed to enable the study of ‘subjectivity’: views, opinions, beliefs, values, tastes, preferences…

“Only subjective opinions are at

issue in Q, and although they are

typically unprovable, they can

nonetheless be shown to have

structure and form, and it is the task

of Q technique to render this form

manifest for purposes of observation

and study.”

Brown, 1986, p. 58

Page 9: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

• What goes in:

– People’s rank ordering of statements of opinion

– Their explanations of why

• What we do:

– Look for patterns between those orderings

– Interpret the patterns

• What comes out:

– Rich descriptions of a small number of shared views

– Distinguishing and consensus issues

A little more bit about Q methodology

Page 10: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

FACTOR A

FACTOR B

FACTOR C

Page 11: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

A little more bit about Q methodology

• What goes in:

– People’s rank ordering of statements of opinion

– Their explanations of why

• What we do:

– Look for patterns between those orderings

– Interpret the patterns

• What comes out:

– Rich descriptions of a small number of shared views

– Distinguishing and consensus issues

Page 12: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

A little bit about Q & survey

• New grounds

– Develop and test five approaches

– Today we focus on one approach

Page 13: Rachel Baker, Helen Mason &  Neil  McHugh  Glasgow Caledonian University

Three presentations

• Identifying societal perspectives on the relative value of life extending end of life technologiesRachel Baker

• Investigating the prevalence and distribution of views across the UK populationHelen Mason

• Life-extending technologies for terminally ill patients: views v policy choicesNeil McHugh